In a prospective study of HER2 positive and triple negative breast cancer patients, designed to identify exceptional responders for consideration of omission of axillary surgery following NAC, residual disease in the breast was associated with a relative risk of positive nodal metastasis of 7.4 (95% CI, 3.7–14.8; p < 0.001) [22]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.